Details of Drug

Drug General Information (ID: D1102)
Drug Name	Nalidixic acid
Drug Type	Small molecule
Drug Synonymous	Betaxina; Cybis; Dixiben; Dixinal; Eucistin; Innoxalon; Jicsron; Kusnarin; Nalidicron; Nalidixan; Nalidixane; Nalidixate; Nalidixic; Nalidixin; Nalitucsan; Nalix; Nalurin; Narigix; Naxuril; NegGram; Negram; Nevigramon; Nicelate; Nogram; Poleon; Sicmylon; Specifen; Specifin; Unaserus; Uralgin; Uriben; Uriclar; Urisal; Urodixin; Uroman; Uroneg; Uronidix; Uropan; Wintomylon; Wintron; Acide nalidixico; Acide nalidixico [Italian]; Acide nalidixique; Acide nalidixique [French]; Acido nalidissico; Acido nalidissico [DCIT]; Acido nalidixico; Acidum nalidixicum; NALIDIXATE SODIUM; Naladixic acid; Naldixic acid; Nalidic acid; Nalidixinic acid; Nalidixic acid USP27; WIN 183203; Acid, Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; N-1200; NegGram (TN); Neggram (TN); Sodium Nalidixic Acid, Anhydrous; Sodium Nalidixic Acid, Monohydrate; Sodium,Nalidixate; WIN 18,320; WIN-18320; Wil 18,320; Wintomylon (TN); ZERO/002632; WIN-18320 (TN); Nalidixic acid (JP15/USP/INN); Nalidixic acid [USAN:INN:BAN:JAN]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one Click to Show/Hide
Disease Class	GC08: Urinary tract infection
Therapeutic Class	Antibiotics
Structure
Structure	3D Structure		2D Structure
Formula	C12H12N2O3
InChI	1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
InChIKey	MHWLWQUZZRMNGJ-UHFFFAOYSA-N
Canonical SMILES	CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O
External Link
	Pubchem ID	4421
	CAS Number	389-08-2
	CHEBI ID	100147
	TTD ID	D07JGT
	INTEDE ID	DR2296

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM003 Affected organization distribution AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM002 Altered intestinal flora BM003 Complex formation BM006 Altered intestinal mucosa BM014 Interference of cell/tissue uptake BM017 CYP450 enzyme inhibition BM028 Competitive inhibition of renal tubular secretion BM029 Altered urine pH BM038 Additive CNS depression effects BM039 Additive CNS stimulant effects BM050 Increased risk of bleeding BM054 Increased risk of GI mucosal injury/bleeding risk BM064 Increased risk of hypoglycemia BM069 Increased risk of lowers seizure threshold BM072 Increased risk of nephrotoxicity BM075 Increased risk of photosensitivity reactions BM080 Increased risk of tendinitis/tendon rupture BM086 Antagonize the effect of antidiabetic agents BM089 Antagonize the effect of antihypertensive agents BM100 Antagonize the effect of vaccine/toxoid BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Nalidixic acid
Affected gastrointestinal absorption
	Altered intestinal flora					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1094		Mycophenolate mofetil	C23H31NO7	5281078	Moderate		Inter Info	[100], [101]
D1095		Mycophenolic acid	C17H20O6	446541	Moderate		Inter Info	[100], [101]
	Complex formation					Drug Num: 32
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0235		Calcium acetate	C4H6CaO4	6116	Moderate		Inter Info	[8]
D0975		Magnesium sulfate	MgO4S	24083	Moderate		Inter Info	[8]
D0049		Aluminum hydroxide	AlH3O3	10176082	Moderate		Inter Info	[8]
D0236		Calcium carbonate	CCaO3	10112	Moderate		Inter Info	[8]
D0238		Calcium citrate	C12H10Ca3O14	13136	Moderate		Inter Info	[8]
D0239		Calcium glubionate anhydrous	C18H32CaO19	64776	Moderate		Inter Info	[8]
D0241		Calcium gluconate	C12H22CaO14	9290	Moderate		Inter Info	[8]
D0243		Calcium lactate	C6H10CaO6	13144	Moderate		Inter Info	[8]
D0244		Calcium Phosphate	Ca3O8P2	24456	Moderate		Inter Info	[8]
D0483		Didanosine	C10H12N4O3	135398739	Moderate		Inter Info	[122], [123], [124], [69], [5], [8], [125], [126], [127], [128]
D0619		Ethinylestradiol	C20H24O2	5991	Moderate		Inter Info	[129], [130], [131]
D0649		Ferrous fumarate	C4H2FeO4	6433164	Moderate		Inter Info	[8]
D0650		Ferrous gluconate	C12H22FeO14	23616740	Moderate		Inter Info	[8]
D0651		Ferrous sulfate anhydrous	FeO4S	24393	Moderate		Inter Info	[8]
D0847		Iron	Fe	23925	Moderate		Inter Info	[8]
D0877		Kaolin	Al2H4O9Si2	56841936	Moderate		Inter Info	[8]
D0893		Lanthanum carbonate	C3La2O9	168924	Moderate		Inter Info	[19], [37], [38], [141], [142], [143]
D0968		Magnesium carbonate	CMgO3	11029	Moderate		Inter Info	[8]
D0969		Magnesium chloride	Cl2H12MgO6	643991	Moderate		Inter Info	[8]
D0970		Magnesium citrate	C12H10Mg3O14	6099959	Moderate		Inter Info	[8]
D0971		Magnesium gluconate	C12H22MgO14	11418570	Moderate		Inter Info	[8]
D0973		Magnesium hydroxide	H2MgO2	14791	Moderate		Inter Info	[8]
D0974		Magnesium oxide	MgO	14792	Moderate		Inter Info	[8]
D1011		Mestranol	C21H26O2	6291	Moderate		Inter Info	[129], [130], [131]
D1369		Quinapril	C25H30N2O5	54892	Moderate		Inter Info	[38], [96]
D1456		Selenium	Se	6326970	Moderate		Inter Info	[8]
D1566		Tetraferric tricitrate decahydrate	C18H32Fe4O31	90478690	Moderate		Inter Info	[8]
D1722		Zinc acetate	C4H6O4Zn	11192	Moderate		Inter Info	[8]
D1724		Zinc gluconate	C12H22O14Zn	443445	Moderate		Inter Info	[8]
D1725		Zinc sulfate	O4SZn	24424	Moderate		Inter Info	[8]
D1462		Sevelamer	C6H12ClNO	3085017	Moderate		Inter Info	[154]
D1511		Sucralfate	C12H54Al9O55S8	121494085	Moderate		Inter Info	[8]
	Altered intestinal mucosa					Drug Num: 41
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0030		Aldesleukin	NA	NA	Minor		Inter Info	[93]
D0048		Altretamine	C9H18N6	2123	Minor		Inter Info	[93]
D0190		Bleomycin	C55H84N17O21S3+	5360373	Minor		Inter Info	[93]
D0344		Cisplatin	Cl2H6N2Pt	5702198	Minor		Inter Info	[93]
D0357		Clofarabine	C10H11ClFN5O3	119182	Minor		Inter Info	[93]
D0429		Daunorubicin	C27H29NO10	30323	Minor		Inter Info	[93]
D0430		Daunorubicin (liposomal)	C27H29NO10	30323	Minor		Inter Info	[93]
D0442		Denileukin diftitox	NA	NA	Minor		Inter Info	[93]
D0584		Epirubicin	C27H29NO11	41867	Minor		Inter Info	[93]
D0627		Etoposide	C29H32O13	36462	Minor		Inter Info	[93]
D0666		Floxuridine	C9H11FN2O5	5790	Minor		Inter Info	[93]
D0675		Fluorouracil	C4H3FN2O2	3385	Minor		Inter Info	[93]
D0714		Gemcitabine	C9H11F2N3O4	60750	Minor		Inter Info	[93]
D0717		Gemtuzumab ozogamicin	NA	NA	Minor		Inter Info	[93]
D0845		Irinotecan	C33H38N4O6	60838	Minor		Inter Info	[93]
D1077		Mitomycin	C15H18N4O5	5746	Minor		Inter Info	[93]
D0249		Capecitabine	C15H22FN3O6	60953	Minor		Inter Info	[93]
D0260		Carboplatin	C6H12N2O4Pt	426756	Minor		Inter Info	[93]
D0404		Cytarabine	C9H13N3O5	6253	Minor		Inter Info	[93]
D0410		Dactinomycin	C62H86N12O16	457193	Minor		Inter Info	[93]
D0511		Docetaxel	C43H53NO14	148124	Minor		Inter Info	[93]
D0528		Doxorubicin	C27H29NO11	31703	Minor		Inter Info	[93]
D0669		Fludarabine	C10H12FN5O4	657237	Minor		Inter Info	[93]
D0780		Hydroxyurea	CH4N2O2	3657	Minor		Inter Info	[93]
D0788		Idarubicin	C26H27NO9	42890	Minor		Inter Info	[93]
D0962		Lurbinectedin	C41H44N4O10S	57327016	Minor		Inter Info	[93]
D1007		Mercaptopurine	C5H4N4S	667490	Minor		Inter Info	[93]
D1079		Mitoxantrone	C22H28N4O6	4212	Minor		Inter Info	[93]
D1212		Paclitaxel	C47H51NO14	36314	Minor		Inter Info	[93]
D1213		Paclitaxel (protein-bound)	C47H51NO14	36314	Minor		Inter Info	[93]
D1345		Procarbazine	C12H19N3O	4915	Minor		Inter Info	[93]
D1548		Temozolomide	C6H6N6O2	5394	Minor		Inter Info	[93]
D1610		Topotecan	C23H23N3O5	60700	Minor		Inter Info	[93]
D1250		Pentostatin	C11H16N4O4	439693	Minor		Inter Info	[93]
D1551		Teniposide	C32H32O13S	452548	Minor		Inter Info	[93]
D1589		Tioguanine	C5H5N5S	2723601	Minor		Inter Info	[93]
D1626		Tretinoin	C20H28O2	444795	Minor		Inter Info	[93]
D1697		Vinblastine	C46H58N4O9	13342	Minor		Inter Info	[93]
D1698		Vincristine	C46H56N4O10	5978	Minor		Inter Info	[93]
D1699		Vincristine (liposome)	C46H56N4O10	5978	Minor		Inter Info	[93]
D1700		Vinorelbine	C45H54N4O8	5311497	Minor		Inter Info	[93]
Affected organization distribution
	Interference of cell/tissue uptake					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1817		Indium In-111 oxyquinoline	C27H18InN3O3	16685037	Moderate		Inter Info	[140]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 17
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0370		Clozapine	C18H19ClN4	135398737	Major		Inter Info	[11], [12], [13], [14]
D1385		Rasagiline	C12H13N	3052776	Major		Inter Info	[37], [38], [39]
D1596		Tizanidine	C9H8ClN5S	5487	Major		Inter Info	[43], [44], [45], [46], [47], [48], [49], [50]
D0084		Anagrelide	C10H7Cl2N3O	135409400	Moderate		Inter Info	[59]
D0231		Caffeine	C8H10N4O2	2519	Moderate		Inter Info	[60], [61], [62], [63], [64], [65], [66], [12], [67], [68], [69], [5], [70], [71], [72], [73], [74]
D0539		Duloxetine	C18H19NOS	60835	Moderate		Inter Info	[85], [86], [87], [88]
D0043		Alosetron	C17H18N4O	2099	Moderate		Inter Info	[102]
D0064		Aminophylline	C16H24N10O4	9433	Moderate		Inter Info	[84], [106], [107], [108], [109], [110], [111], [112], [83], [113], [114], [115], [81], [116], [117], [118]
D0112		Asenapine	C17H16ClNO	3036780	Moderate		Inter Info	[119]
D0157		Bendamustine	C16H21Cl2N3O2	65628	Moderate		Inter Info	[121]
D1378		Ramelteon	C16H21NO2	208902	Moderate		Inter Info	[147]
D1505		Stiripentol	C14H18O3	5311454	Moderate		Inter Info	[38], [148], [149]
D1536		Tasimelteon	C15H19NO2	10220503	Moderate		Inter Info	[150]
D1427		Ropinirole	C16H24N2O	5095	Moderate		Inter Info	[70], [153]
D1570		Theophylline	C7H8N4O2	2153	Moderate		Inter Info	[84], [106], [107], [108], [109], [110], [111], [112], [83], [113], [114], [115], [81], [116], [117], [118]
D1054		Mexiletine	C11H17NO	4178	Minor		Inter Info	[156], [157]
D0994		Melatonin	C13H16N2O2	896	Minor		Inter Info	[37]
Affected excretion pathways
	Competitive inhibition of renal tubular secretion					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0576		Entecavir	C12H15N5O3	135398508	Moderate		Inter Info	[89]
D1025		Methotrexate	C20H22N8O5	126941	Moderate		Inter Info	[93], [94], [95]
D1341		Probenecid	C13H19NO4S	4911	Moderate		Inter Info	[146], [8]
	Altered urine pH					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1760		Citric acid	C6H8O7	311	Moderate		Inter Info	[96], [5]
D1319		Potassium citrate	C6H5K3O7	13344	Moderate		Inter Info	[96], [5]
D1480		Sodium bicarbonate	CHNaO3	516892	Moderate		Inter Info	[96], [5]
D1483		Sodium citrate	C6H5Na3O7	6224	Moderate		Inter Info	[96], [5]
Pharmacodynamic additive effects
	Additive CNS depression effects					Drug Num: 10
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0298		Celecoxib	C17H14F3N3O2S	2662	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0476		Diclofenac	C14H11Cl2NO2	3033	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0624		Etodolac	C17H21NO3	3308	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0645		Fenoprofen	C15H14O3	3342	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0680		Flurbiprofen	C15H13FO2	3394	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0800		Indomethacin	C19H16ClNO4	3715	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0882		Ketorolac	C15H13NO3	3826	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0489		Diflunisal	C13H8F2O3	3059	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0786		Ibuprofen	C13H18O2	3672	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0881		Ketoprofen	C16H14O3	3825	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
	Additive CNS stimulant effects					Drug Num: 13
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1097		Nabumetone	C15H16O2	4409	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0017		Acetylsalicylic acid	C9H8O4	2244	Moderate		Inter Info	[3], [75], [78]
D0331		Choline salicylate	C12H19NO4	54686350	Moderate		Inter Info	[78], [3], [75]
D0988		Meclofenamic acid	C14H11Cl2NO2	4037	Moderate		Inter Info	[78], [3], [75]
D0991		Mefenamic acid	C15H15NO2	4044	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D0995		Meloxicam	C14H13N3O4S2	54677470	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D1109		Naproxen	C14H14O3	156391	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D1196		Oxaprozin	C18H15NO3	4614	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D1272		Phenyl salicylate	C13H10O3	8361	Moderate		Inter Info	[78], [3], [75]
D1442		Salsalate	C14H10O5	5161	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D1300		Piroxicam	C15H13N3O4S	54676228	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D1520		Sulindac	C20H17FO3S	1548887	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
D1606		Tolmetin	C15H15NO3	5509	Moderate		Inter Info	[75], [72], [5], [3], [76], [77], [78], [79], [80], [81], [82], [83], [84], [6]
	Increased risk of bleeding					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1711		Warfarin	C19H16O4	54678486	Major		Inter Info	[53], [54], [55]
	Increased risk of GI mucosal injury/bleeding risk					Drug Num: 11
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0264		Carmustine	C5H9Cl2N3O2	2578	Major		Inter Info	[8]
D0312		Chlorambucil	C14H19Cl2NO2	2708	Major		Inter Info	[8]
D0400		Cyclophosphamide	C7H15Cl2N2O2P	2907	Major		Inter Info	[8]
D0223		Busulfan	C6H14O6S2	2478	Major		Inter Info	[8]
D0407		Dacarbazine	C6H10N6O	135398738	Major		Inter Info	[8]
D0790		Ifosfamide	C7H15Cl2N2O2P	3690	Major		Inter Info	[8]
D0945		Lomustine	C9H16ClN3O2	3950	Major		Inter Info	[8]
D0986		Mechlorethamine	C5H11Cl2N	4033	Major		Inter Info	[8]
D0996		Melphalan	C13H18Cl2N2O2	460612	Major		Inter Info	[8]
D1575		Thiotepa	C6H12N3PS	5453	Major		Inter Info	[8]
D1508		Streptozocin	C8H15N3O7	29327	Major		Inter Info	[8]
	Increased risk of hypoglycemia					Drug Num: 15
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0009		Acarbose	C25H43NO18	41774	Moderate		Inter Info	[56], [57], [58]
D1015		Metformin	C4H11N5	4091	Moderate		Inter Info	[56], [57], [58]
D1064		Miglitol	C8H17NO5	441314	Moderate		Inter Info	[56], [57], [58]
D0029		Albiglutide	C148H224N40O45	145994868	Moderate		Inter Info	[56], [57], [58]
D0042		Alogliptin	C18H21N5O2	11450633	Moderate		Inter Info	[56], [57], [58]
D0245		Canagliflozin	C24H25FO5S	24812758	Moderate		Inter Info	[56], [57], [58]
D0418		Dapagliflozin	C21H25ClO6	9887712	Moderate		Inter Info	[56], [57], [58]
D0565		Empagliflozin	C23H27ClO7	11949646	Moderate		Inter Info	[56], [57], [58]
D0930		Linagliptin	C25H28N8O2	10096344	Moderate		Inter Info	[56], [57], [58]
D0941		Lixisenatide	C215H347N61O65S	90472060	Moderate		Inter Info	[56], [57], [58]
D1294		Pioglitazone	C19H20N2O3S	4829	Moderate		Inter Info	[56], [57], [58]
D1326		Pramlintide	C171H267N51O53S2	70691388	Moderate		Inter Info	[56], [57], [58]
D1449		Saxagliptin	C18H25N3O2	11243969	Moderate		Inter Info	[56], [57], [58]
D1477		Sitagliptin	C16H15F6N5O	4369359	Moderate		Inter Info	[56], [57], [58]
D1429		Rosiglitazone	C18H19N3O3S	77999	Moderate		Inter Info	[56], [57], [58]
	Increased risk of lowers seizure threshold					Drug Num: 9
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0220		Bupropion	C13H18ClNO	444	Major		Inter Info	[17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31]
D0833		Iohexol	C19H26I3N3O9	3730	Major		Inter Info	[32], [33], [34], [35], [36]
D0834		Iopamidol	C17H22I3N3O8	65492	Major		Inter Info	[32], [33], [34], [35], [36]
D1616		Tramadol	C16H25NO2	33741	Major		Inter Info	[51], [30], [29], [52]
D0678		Fluphenazine	C22H26F3N3OS	3372	Moderate		Inter Info	[37], [38]
D0932		Lindane	C6H6Cl6	727	Moderate		Inter Info	[90], [91], [92]
D0054		Amifampridine	C5H7N3	5918	Moderate		Inter Info	[103], [104]
D0722		Ginkgo biloba	NA	NA	Moderate		Inter Info	[132], [133], [134], [135], [136], [137], [138], [139]
D1308		Polyethylene glycol (3350 with electrolytes)	C2H6O2	174	Moderate		Inter Info	[144], [145], [38]
	Increased risk of nephrotoxicity					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0292		Ceftazidime	C22H22N6O7S2	5481173	Moderate		Inter Info	[37], [38]
D0724		Givosiran	C78H139N11O30	119058042	Moderate		Inter Info	[37], [38]
D1304		Plazomicin	C25H48N6O10	42613186	Moderate		Inter Info	[37], [38]
D1526		Tacrolimus	C44H69NO12	445643	Moderate		Inter Info	[37], [38]
D1138		Nimodipine	C21H26N2O7	4497	Moderate		Inter Info	[37], [38]
	Increased risk of photosensitivity reactions					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1028		Methoxsalen	C12H8O4	4114	Moderate		Inter Info	[37], [96], [97], [98], [99]
D0063		Aminolevulinic acid (topical)	C5H9NO3	137	Moderate		Inter Info	[37], [38], [105]
D1033		Methyl aminolevulinate (topical)	C6H11NO3	157922	Moderate		Inter Info	[37], [38], [105]
D1314		Porfimer sodium	C68H74N8O11	135577896	Moderate		Inter Info	[151], [38], [152]
D1691		Verteporfin	C82H84N8O16	11980904	Moderate		Inter Info	[38], [96], [97], [155]
	Increased risk of tendinitis/tendon rupture					Drug Num: 10
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0172		Betamethasone	C22H29FO5	9782	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
D0671		Fludrocortisone	C21H29FO5	31378	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
D0773		Hydrocortisone	C21H30O5	5754	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
D0155		Bempedoic acid	C19H36O5	10472693	Major		Inter Info	[15], [16]
D0436		Deflazacort	C25H31NO6	189821	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
D0453		Dexamethasone	C22H29FO5	5743	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
D1041		Methylprednisolone	C22H30O5	6741	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
D1332		Prednisolone	C21H28O5	5755	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
D1334		Prednisone	C21H26O5	5865	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
D1628		Triamcinolone	C21H27FO6	31307	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
Pharmacodynamic antagonistic effects
	Antagonize the effect of antidiabetic agents					Drug Num: 19
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0325		Chlorpropamide	C10H13ClN2O3S	2727	Major		Inter Info	[9], [5], [10]
D0727		Glimepiride	C24H34N4O5S	3476	Major		Inter Info	[9], [5], [10]
D0811		Insulin glargine	C267H404N72O78S6	118984454	Major		Inter Info	[9], [5], [10]
D0814		Insulin human (inhalation, rapid acting)	C257H383N65O77S6	118984375	Major		Inter Info	[9], [5], [10]
D0815		Insulin human (isophane)	C257H383N65O77S6	118984375	Major		Inter Info	[9], [5], [10]
D0816		Insulin human (regular)	C257H383N65O77S6	118984375	Major		Inter Info	[9], [5], [10]
D0817		Insulin human (zinc extended)	C257H383N65O77S6	118984375	Major		Inter Info	[9], [5], [10]
D0818		Insulin human (zinc)	C257H383N65O77S6	118984375	Major		Inter Info	[9], [5], [10]
D0819		Insulin lispro	C257H389N65O77S6	16132438	Major		Inter Info	[9], [5], [10]
D0728		Glipizide	C21H27N5O4S	3478	Major		Inter Info	[9], [5], [10]
D0730		Glyburide	C23H28ClN3O5S	3488	Major		Inter Info	[9], [5], [10]
D0808		Insulin aspart (aspart)	C256H381N65O79S6	118984445	Major		Inter Info	[9], [5], [10]
D0809		Insulin degludec	C274H411N65O81S6	118984462	Major		Inter Info	[9], [5], [10]
D0810		Insulin detemir	C267H402N64O76S6	16137271	Major		Inter Info	[9], [5], [10]
D0812		Insulin glulisine	C258H384N64O78S6	16136701	Major		Inter Info	[9], [5], [10]
D1392		Repaglinide	C27H36N2O4	65981	Major		Inter Info	[9], [5], [10]
D1601		Tolazamide	C14H21N3O3S	5503	Major		Inter Info	[9], [5], [10]
D1603		Tolbutamide	C12H18N2O3S	5505	Major		Inter Info	[9], [5], [10]
D1112		Nateglinide	C19H27NO3	5311309	Major		Inter Info	[9], [5], [10]
	Antagonize the effect of antihypertensive agents					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1779		Dulaglutide	NA	NA	Moderate		Inter Info	[56], [57], [58]
D1782		Ertugliflozin	C22H25ClO7	44814423	Moderate		Inter Info	[56], [57], [58]
D1784		Exenatide	C184H282N50O60S	45588096	Moderate		Inter Info	[56], [57], [58]
D1887		Semaglutide	C187H291N45O59	56843331	Moderate		Inter Info	[56], [57], [58]
	Antagonize the effect of vaccine/toxoid					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1914		Typhoid vaccine (live)	NA	NA	Major		Inter Info	[38], [40], [41]
D1693		Vibrio cholerae CVD 103-HgR strain live antigen (live)	NA	NA	Major		Inter Info	[42]
	Attenuated pharmacological effects (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0145		Balsalazide	C17H15N3O6	54585	Moderate		Inter Info	[120]

References
1	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
2	Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410. [PMID: 12766835]
3	Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
4	Product Information. Baxdela (delafloxacin). Melinta Therapeutics, Lincolnshire, IL.
5	Product Information. Cipro (ciprofloxacin). Bayer, West Haven, CT.
6	Product Information. Levaquin (levofloxacin). Ortho Pharmaceutical Corporation, Raritan, NJ.
7	van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7. [PMID: 12912715]
8	Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.
9	Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006): 1352-61. [PMID: 16510739]
10	Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004): 111-7. [PMID: 15321742]
11	Fuhr U, Anders EM, Mahr G, Sorgel F, Staid AH "Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro." Antimicrob Agents Chemother 36 (1992): 942-8. [PMID: 1510417]
12	Kinzig-Schippers M, Fuhr U, Zaigler M, et al "Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2." Clin Pharmacol Ther 65 (1999): 262-74. [PMID: 10096258]
13	Markowitz JS, Gill HS, Devane CL, Mintzer JE "Fluoroquinolone inhibition of clozapine metabolism." Am J Psychiatry 154 (1997): 881. [PMID: 9167522]
14	Raaska K, Neuvonen PJ "Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia." Eur J Clin Pharmacol 56 (2000): 585-9. [PMID: 11151749]
15	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
16	Product Information. Nexlizet (bempedoic acid-ezetimibe). Esperion Therapeutics, Ann Arbor, MI.
17	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
18	Sheehan DV, Welch JB, Fishman SM "A case of bupropion-induced seizure." J Nerv Ment Dis 174 (1986): 496-8. [PMID: 3090199]
19	Canadian Pharmacists Association.
20	Product Information. Wellbutrin (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
21	Gittelman DK, Kirby MG "A seizure following bupropion overdose." J Clin Psychiatry 54 (1993): 162. [PMID: 8486598]
22	Product Information. Wellbutrin SR (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
23	James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
24	Masco HL, Kiev A, Holloman LC, Batey SR, Johnston JA, Lineberry CG "Safety and efficacy of bupropion and nortriptyline in outpatients with depression." Curr Ther Res Clin Exp 55 (1994): 851-63.
25	Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
26	Product Information. Zyban (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
27	Storrow AB "Bupropion overdose and seizure." Am J Emerg Med 12 (1994): 183-4. [PMID: 8161393]
28	Johnston JA, Lineberry CG, Ascher JA, et al. "A 102-center prospective study of seizure in association with bupropion." J Clin Psychiatry 52 (1991): 450-6. [PMID: 1744061]
29	Rosenstein DL, Nelson JC, Jacobs SC "Seizures associated with antidepressants: a review." J Clin Psychiatry 54 (1993): 289-99. [PMID: 8253696]
30	Pisani F, Spina E, Oteri G "Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice." Epilepsia 40(Suppl 10) (1999): S48-56. [PMID: 10609604]
31	Product Information. Aplenzin (buPROPion). sanofi-aventis , Bridgewater, NJ.
32	Product Information. Isovue-M-200 (iopamidol). Bracco Diagnostics Inc, Princeton, NJ.
33	Product Information. Amipaque (metrizamide) Nycomed Inc, Princeton, NJ.
34	Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35. [PMID: 810000]
35	Product Information. Omnipaque 180 (iohexol). Amersham Health, Princeton, NJ.
36	Product Information. Osmovist 240 (iotrolan). Berlex Canada Inc, Lachine, QC.
37	Cerner Multum, Inc. "Australian Product Information.".
38	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
39	Product Information. Azilect (rasagiline). Teva Pharmaceuticals USA, North Wales, PA.
40	UK government "Typhoid.".
41	American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association (1994).
42	Product Information. Vaxchora (cholera vaccine, live). PaxVax, Miami, FL.
43	Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
44	Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ "Fluvoxamine drastically increases concentrations and effects of tizanidine: A potentially hazardous interaction." Clin Pharmacol Ther 75 (2004): 331-41. [PMID: 15060511]
45	Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ "Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism." Clin Pharmacol Ther 76 (2004): 598-606. [PMID: 15592331]
46	Momo K, Doki K, Hosono H, Homma M, Kohda Y "Drug interaction of tizanidine and fluvoxamine." Clin Pharmacol Ther 76 (2004): 509-10. [PMID: 15536467]
47	Momo K, Homma M, Kohda Y, Ohkoshi N, Yoshizawa T, Tamaoka A "Drug interaction of tizanidine and ciprofloxacin: Case report." Clin Pharmacol Ther 80 (2006): 717-9. [PMID: 17178273]
48	Product Information. Vioxx (rofecoxib). Merck & Co, Inc, West Point, PA.
49	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
50	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
51	Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
52	Gardiner JS, Blough D, Drinkard CR, et al. "Tramadol and seizures: a surveillance study in a managed care population." Pharmacotherapy 20 (2000): 1423-31. [PMID: 11130214]
53	Arnold LM, Nissen LR, Ng TM "Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction." Pharmacotherapy 25 (2005): 904-7.[PMID: 15927911]
54	Glasheen JJ, Fugit RV, Prochazka AV "Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy--a comment." Pharmacotherapy 23 (2003): 1079-80 discussion 1080.[PMID: 12921255]
55	Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW "Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation." Pharmacotherapy 12 (1992): 435-9.[PMID: 1492006]
56	Gavin JR 3rd, Kubin R, Choudhri S, et al "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004): 671-86. [PMID: 15230648]
57	Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010): e5-6. [PMID: 20103009]
58	Yip C, Lee AJ "Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature." Clin Ther 28 (2006): 1857-66. [PMID: 17213006]
59	Product Information. Agrylin (anagrelide). Roberts Pharmaceutical Corporation, Eatontown, NJ.
60	Carbo ML, Segura J, De la Torre R, et al "Effect of quinolones on caffeine disposition." Clin Pharmacol Ther 45 (1989): 234-40. [PMID: 2920498]
61	Carrillo JA, Benitez J "Clinically significant pharmacokinetic interactions between dietary caffeine and medications." Clin Pharmacokinet 39 (2000): 127-53. [PMID: 10976659]
62	Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH "Quinolone inhibition of cytochrome P-450 dependent caffeine metabolism in human liver microsomes." Drug Metab Dispos 18 (1990): 1005-10. [PMID: 1981505]
63	Harder S, Fuhr U, Staib AH, Wolf T "Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations." Am J Med 87 (1989): 89-91. [PMID: 2589393]
64	Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM "4-Quinolones inhibit biotransformation of caffeine." Eur J Clin Pharmacol 35 (1988): 651-6. [PMID: 2853056]
65	Healy DP, Polk RE, Kanawati L, Rock DT, Mooney ML "Interaction between oral ciprofloxacin and caffeine in normal volunteers." Antimicrob Agents Chemother 33 (1989): 474-8. [PMID: 2729942]
66	Healy DP, Schoenle JR, Stotka J, Polk RE "Lack of interaction between lomefloxacin and caffeine in normal volunteers." Antimicrob Agents Chemother 35 (1991): 660-4. [PMID: 2069371]
67	Mahr G, Sorgel F, Granneman GR, et al "Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine." Clin Pharmacokinet 22 (1992): 90-7. [PMID: 1319876]
68	Nicolau DP, Nightingale CH, Tessier PR, et al. "The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine." Drugs 49 Suppl 2 (1995): 357-9. [PMID: 8549360]
69	Polk RE "Drug-drug interactions with ciprofloxacin and other fluoroquinolones." Am J Med 87 (1989): s76-81. [PMID: 2686430]
70	Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
71	Product Information. Penetrax (enoxacin). Rhone-Poulenc Rorer, Collegeville, PA. (1993):.
72	Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
73	Staib AH, Stille W, Dietlein G, et al. "Interaction between quinolones and caffeine." Drugs 34 Suppl 1 (1987): 170-4. [PMID: 3481318]
74	Stille W, Harder S, Micke S, et al. "Decrease of caffeine elimination in man during co-administration of 4-quinolones." J Antimicrob Chemother 20 (1987): 729-34. [PMID: 3480885]
75	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
76	Product Information. Floxin (ofloxacin). Ortho Pharmaceutical Corporation, Raritan, NJ.
77	Product Information. Penetrex (enoxacin). Rhone-Poulenc Rorer, Collegeville, PA.
78	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
79	Product Information. Tequin (gatifloxacin) Bristol-Myers Squibb, Princeton, NJ.
80	Ball P, Tillotson G "Tolerability of fluoroquinolone antibiotics: past, present and future." Drug Saf 13 (1996): 343-8. [PMID: 8652079]
81	Segev S. Rehavi M, Rubinstein E "Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor." Antimicrob Agents Chemother 32 (1988): 1624-6. [PMID: 2855295]
82	Domagala JM "Structure-activity and structure-side-effect relationships for the quinolone antibacterials." J Antimicrob Chemother 33 (1994): 685-706. [PMID: 8056688]
83	Hooper DC, Wolfson JS "The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans." Antimicrob Agents Chemother 28 (1985): 716-21. [PMID: 2936302]
84	Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986): 187-93. [PMID: 3542945]
85	Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4. [PMID: 8466541]
86	Martinez C, Albet C, Agundez JA, et al. "Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists." Clin Pharmacol Ther 65 (1999): 369-76. [PMID: 10223772]
87	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
88	Uwe F, Strobl G, Manaut F, et al "Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isofaorm CYP1A2." Mol Pharmacol 43 (1993): 191-9. [PMID: 8429824]
89	Product Information. Baraclude (entecavir). Bristol-Myers Squibb, Princeton, NJ.
90	Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
91	Cox R, Krupnick J, Bush N, Houpt A "Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder." J Miss State Med Assoc 41 (2000): 690-2. [PMID: 10974795]
92	Product Information. Kwell (lindane). Reed and Carnrick, Jersey City, NJ.
93	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
94	Nesher G, Mates M, Zevin S "Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis." Arthritis Rheum 48 (2003): 571-572. [PMID: 12571869]
95	Dalle JH, Auvrignon A, Vassal G, Leverger G "Interaction Between Methotrexate and Ciprofloxacin." J Pediatr Hematol Oncol 24 (2002): 321-322
96	Multum Information Services, Inc. Expert Review Panel.
97	Product Information. Nulibry (fosdenopterin). Origin Biosciences Inc, Boston, MA.
98	Product Information. Oxsoralen (methoxsalen). ICN Pharmaceuticals Inc, Costa Mesa, CA.
99	Product Information. Uvadex (methoxsalen). Therakos Inc, Exton, PA.
100	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
101	Product Information. Myfortic (mycophenolic acid). Novartis Pharmaceuticals, East Hanover, NJ.
102	Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
103	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
104	Product Information. Firdapse (amifampridine). Catalyst Pharmaceuticals, Inc., Coral Gables, FL.
105	Product Information. Metvixia (methyl aminolevulinate topical). Galderma Laboratories Inc, Cranbury, NJ.
106	Bowles SK, Popovski Z, Rybak MJ, Beckman HB, Edwards DJ "Effect of norfloxacin on theophylline pharmacokinetics at steady state." Antimicrob Agents Chemother 32 (1988): 510-12. [PMID: 3377462]
107	Covelli HD, Knodel AR, Heppner BT "Predisposing factors to apparent theophylline-induced seizures." Ann Allergy 54 (1985): 411-5. [PMID: 3994071]
108	Davis RL, Kelly HW, Quenzer RW, Standefer J, Steinberg B, Gallegos J "Effect of norfloxacin on theophyllin metabolism." Antimicrob Agents Chemother 33 (1989): 212-4. [PMID: 2719466]
109	Grasela TH, Dreis MW "An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system." Arch Intern Med 152 (1992): 617-21. [PMID: 1312320]
110	Green L, Clark J "Fluoroquinolones and theophylline toxicity: norfloxacin." JAMA 262 (1989): 2383. [PMID: 2795820]
111	Gregoire SL, Grasela TH Jr, Freer JP, Tack KJ, Schentag JJ "Inhibition of theophylline clearance by coadministered ofloxacin without alteraction of theophylline effects." Antimicrob Agents Chemother 31 (1987): 375-8. [PMID: 3472488]
112	Ho G, Tierney MG, Dales RE "Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline." Clin Pharmacol Ther 44 (1988): 35-8. [PMID: 3391003]
113	Product Information. Cinobac (cinoxacin). Oclassen Pharmaceuticals Inc, San Rafael, CA.
114	Raoof S, Wollschlager C, Khan FA "Ciprofloxacin increases serum levels of theophylline." Am J Med 82 (1987): 115-8. [PMID: 3578320]
115	Sano M, Yamamoto I, Ueda J, Yoskikawa E, Yamashina H, Goto M "Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration." Eur J Clin Pharmacol 32 (1987): 431-2. [PMID: 3475207]
116	Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part I)." Clin Pharmacokinet 20 (1991): 66-80. [PMID: 1674242]
117	Wijnands WJ, Vree TB "Interaction between the fluoroquinolones and the bronchodilator theophylline." J Antimicrob Chemother 22 (1988): 109-14. [PMID: 3053575]
118	Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL "Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintneance treatment with theophylline." Drugs 34 (1987): 159-69. [PMID: 3481317]
119	Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
120	Product Information. Colazal (balsalazide) Salix Pharmaceuticals, Palo Alto, CA.
121	Product Information. Treanda (bendamustine). Cephalon Inc, West Chester, PA.
122	Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
123	Knupp CA, Barbhaiya RH "A multiple-dose pharmacokinetic interaction study between didanosine (videx(r)) and ciprofloxacin (cipro(r)) in male subjects seropositive for HIV but asymptomatic." Biopharm Drug Dispos 18 (1997): 65-77. [PMID: 9008270]
124	Marchbanks CR "Drug-drug interactions with fluoroquinolones." Pharmacotherapy 13 (1993): s23-8. [PMID: 8474934]
125	Product Information. Videx (didanosine). Bristol-Myers Squibb, Princeton, NJ.
126	Sahai J "Avoiding the ciprofloxacin-didanosine interaction." Ann Intern Med 123 (1995): 394-5. [PMID: 7625638]
127	Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G "Cations in the didanosine tablet reduce ciprofloxacin bioavailability." Clin Pharmacol Ther 53 (1993): 292-7. [PMID: 8453847]
128	Damle BD, Mummaneni V, Kaul S, Knupp C "Lack of Effect of Simultaneously Administered Didanosine Encapsulated Enteric Bead Formulation (Videx EC) on Oral Absorption of Indinavir, Ketoconazole, or Ciprofloxacin." Antimicrob Agents Chemother 46 (2002): 385-91. [PMID: 11796346]
129	Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
130	Kleier DJ, Tucker JE "Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?" J Colo Dent Assoc 66 (1987): 5-6. [PMID: 3478352]
131	Silber TJ "Apparent oral contraceptive failure associated with antibiotic administration." J Adolesc Health Care 4 (1983): 287-9. [PMID: 6643209]
132	Kajiyama Y, Fujii K, Takeuchi H, Manabe Y "Ginkgo seed poisoning." Pediatrics 109 (2002): 325-7. [PMID: 11826216]
133	Granger AS "Ginkgo biloba precipitating epileptic seizures." Age Ageing 30 (2001): 523-5. [PMID: 11742783]
134	Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11. [PMID: 9818800]
135	Spinella M "Herbal medicines and epilepsy: the potential for benefit and adverse effects." Epilepsy Behav 2 (2001): 524-32. [PMID: 12609386]
136	Gregory PJ "Seizure associated with Ginkgo biloba?." Ann Intern Med 134 (2001): 344. [PMID: 11182853]
137	Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE "Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder." Epilepsia 47 (2006): 323-9. [PMID: 16499756]
138	Miwa H, Iijima M, Tanaka S, Mizuno Y "Generalized convulsions after consuming a large amount of Gingko nuts." Epilepsia 42 (2001): 280-1. [PMID: 11240603]
139	Kupiec T, Raj V "Fatal seizures due to potential herb-drug interactions with Ginkgo biloba." J Anal Toxicol 29 (2005): 755-8. [PMID: 16419414]
140	Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111). GE Healthcare, Princeton, NJ.
141	Product Information. Fosrenol (lanthanum carbonate). Shire US Inc, Florence, KY.
142	Product Information. Nuzyra (omadacycline). Paratek Pharmaceuticals, Inc., Boston, MA.
143	Product Information. Seysara (sarecycline). Allergan Inc, Irvine, CA.
144	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
145	Salik JM, Kurtin P "Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome." Am J Gastroenterol 80 (1985): 177-9. [PMID: 2983533]
146	Dash H, Mills J "Letter: Severe metabolic acidosis associated with nalidixic acid overdose." Ann Intern Med 84 (1976): 570-1. [PMID: 1275361]
147	Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
148	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
149	Product Information. Diacomit (stiripentol). Biocodex Inc, Creswell, OR.
150	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
151	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
152	Product Information. Photofrin (porfimer). Sanofi Winthrop Pharmaceuticals, New York, NY.
153	Product Information. Requip (ropinirole). SmithKline Beecham, Philadelphia, PA.
154	Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM "Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin." Am J Kidney Dis 42 (2003): 1253-9. [PMID: 14655198]
155	Product Information. Visudyne (verteporfin) Valeant Pharmaceuticals, Costa Mesa, CA.
156	Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.?Clin Pharmacol Ther. 2004;76(6):598-606. [PMID: 15592331]
157	McLellan RA, Drobitch RK, Monshouwer M, Renton KW "Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human." Drug Metab Dispos 24 (1996): 1134-8. [PMID: 8894516]

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence